{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:06:44Z","timestamp":1787843204935,"version":"build-2784847793"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Anaesthesiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bpa.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T14:31:57Z","timestamp":1530541917000},"page":"187-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Perioperative implications of common and newer psychotropic medications used in clinical practice"],"prefix":"10.1016","volume":"32","author":[{"given":"Alan D.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish B.","family":"Siddaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Urman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpa.2018.06.002_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0019-5545.183771","article-title":"Classification of psychotropic drugs: problems, solutions, and more problems","volume":"58","author":"Sathyanarayana Rao","year":"2016","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.bpa.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Per\u00e4l\u00e4","year":"2007","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.002_bib4","series-title":"National survey on drug use and health: mental health findings","author":"Center for Behavioral Health Statistics S","year":"2013"},{"key":"10.1016\/j.bpa.2018.06.002_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bpa.2018.06.002_bib6","unstructured":"NIH Fact Sheets - Parkinson\u2019s Disease n.d."},{"key":"10.1016\/j.bpa.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-2010-100153","article-title":"Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment","volume":"21","author":"Modrego","year":"2010","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.bpa.2018.06.002_bib8","first-page":"177","article-title":"Anaesthetic implications of psychoactive drugs","volume":"10","author":"Peck","year":"2010","journal-title":"Cont Educ Anaesth Crit Care Pain"},{"key":"10.1016\/j.bpa.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1096\/fj.07-1102ufm","article-title":"Science, serotonin, and sadness: the biology of antidepressants","volume":"21","author":"Wrobel","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.bpa.2018.06.002_bib10","article-title":"Dry pipeline for psychiatric drugs - the New York times","author":"Friedman","year":"2013","journal-title":"N\u00a0Y Times"},{"key":"10.1016\/j.bpa.2018.06.002_bib11","series-title":"1 in 6 Americans takes a psychiatric drug \u2013 scientific American","author":"Miller","year":"2016"},{"key":"10.1016\/j.bpa.2018.06.002_bib12","series-title":"The psychiatric drug crisis | the New Yorker. New Yorker","author":"Greenberg","year":"2013"},{"key":"10.1016\/j.bpa.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.12688\/f1000research.10233.1","article-title":"New drugs in psychiatry: focus on new pharmacological targets","volume":"6","author":"Caraci","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.bpa.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bpa.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1176\/appi.psy.47.1.8","article-title":"Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery","volume":"47","author":"Huyse","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bpa.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5049.93337","article-title":"Psychiatric patient and anaesthesia","volume":"56","author":"Attri","year":"2012","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.bpa.2018.06.002_bib17","first-page":"36","article-title":"Vortioxetine (brintellix): a new serotonergic antidepressant","volume":"40","author":"D'Agostino","year":"2015","journal-title":"P\u00a0T"},{"key":"10.1016\/j.bpa.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A\u00a0meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1185\/03007995.2015.1128404","article-title":"Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder","volume":"32","author":"Brignone","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpa.2018.06.002_bib20","unstructured":"Vortioxetine [package insert]. Deerfield, IL; Takeda Pharmaceuticals USA. [n.d]."},{"key":"10.1016\/j.bpa.2018.06.002_bib21","doi-asserted-by":"crossref","first-page":"2020915","DOI":"10.1155\/2016\/2020915","article-title":"Treating chronic pain with SSRIs: what do we know?","volume":"2016","author":"Patetsos","year":"2016","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.bpa.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40264-015-0328-2","article-title":"Selective serotonin reuptake inhibitor use and perioperative bleeding and mortality in patients undergoing coronary artery bypass grafting: a cohort study","volume":"38","author":"Gagne","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpa.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.2014.908182","article-title":"Serotonergic antidepressants and perioperative bleeding risk: a systematic review","volume":"13","author":"Mahdanian","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bpa.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamainternmed.2013.714","article-title":"Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery","volume":"173","author":"Auerbach","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.bpa.2018.06.002_bib25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jclinane.2013.06.005","article-title":"Pharmacogenetic workup of perioperative serotonin syndrome","volume":"25","author":"Beatty","year":"2013","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.bpa.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1213\/XAA.0000000000000217","article-title":"Serotonin syndrome: the potential for a severe reaction between common perioperative medications and selective serotonin reuptake inhibitors","volume":"5","author":"Adler","year":"2015","journal-title":"A\u00a0A Case Reports"},{"key":"10.1016\/j.bpa.2018.06.002_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.bpa.2018.06.002_bib28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s40265-015-0490-y","article-title":"Vilazodone: a review in major depressive disorder in adults","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bpa.2018.06.002_bib29","unstructured":"Vilazodone [package insert]. New Haven, CT; Trovis Pharmaceuticals. [n.d]."},{"key":"10.1016\/j.bpa.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in\u00a0vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.bpa.2018.06.002_bib31","doi-asserted-by":"crossref","unstructured":"Stahl SM. Mechanism of action of cariprazine [n.d.] doi:10.1017\/S1092852916000043.","DOI":"10.1017\/S1092852916000043"},{"key":"10.1016\/j.bpa.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2018.06.002_bib33","series-title":"Cariprazine [package insert]. Parsippany","year":"2017"},{"key":"10.1016\/j.bpa.2018.06.002_bib34","doi-asserted-by":"crossref","first-page":"pyv111","DOI":"10.1093\/ijnp\/pyv111","article-title":"Brexpiprazole alters monoaminergic systems following repeated administration: an in\u00a0vivo electrophysiological study","volume":"19","author":"Oosterhof","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2045125315614739","article-title":"Brexpiprazole: so far so good","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib36","unstructured":"Brexpiprazole [package insert]. Rockville, MD; Otsuka Pharmaceutical Company. [n.d]."},{"key":"10.1016\/j.bpa.2018.06.002_bib37","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1213\/01.ANE.0000184123.67853.86","article-title":"Perioperative management for chronic schizophrenic patients","author":"Kudoh","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpa.2018.06.002_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib39","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis","volume":"36","author":"Fuente-Sandoval de la","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpa.2018.06.002_bib40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.bpa.2018.06.002_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","article-title":"Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia","volume":"66","author":"Kinon","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpa.2018.06.002_bib42","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.002_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jpm6010009","article-title":"Serotonin 2A receptor SNP rs7330461 association with treatment response to pomaglumetad methionil in patients with schizophrenia","volume":"6","author":"Nisenbaum","year":"2016","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.bpa.2018.06.002_bib44","first-page":"758212","article-title":"Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison","volume":"2014","author":"Adams","year":"2014","journal-title":"Schizophr Res Treat"},{"key":"10.1016\/j.bpa.2018.06.002_bib45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejn.12398","article-title":"Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond","volume":"39","author":"Palazzo","year":"2014","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bpa.2018.06.002_bib46","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2174\/138920111798357438","article-title":"Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation","volume":"12","author":"Montana","year":"2011","journal-title":"Curr Pharmaceut Biotechnol"},{"key":"10.1016\/j.bpa.2018.06.002_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.002_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/dta.1425","article-title":"Medical use of cannabis. Cannabidiol: a new light for schizophrenia?","volume":"5","author":"Deiana","year":"2013","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bpa.2018.06.002_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.biopsych.2015.11.018","article-title":"Therapeutic potential of cannabinoids in psychosis","volume":"79","author":"Leweke","year":"2016","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.bpa.2018.06.002_bib50","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bpa.2018.06.002_bib51","series-title":"ClinicalTrials.gov. a four-week clinical trial investigating efficacy and safety of cannabidiol as a treatment for acutely ill schizophrenic patients - full text view \u2013 ClinicalTrials.gov","year":"2014"},{"key":"10.1016\/j.bpa.2018.06.002_bib52","series-title":"FDA briefing document NDA 210365 cannabidiol","year":"2018"},{"key":"10.1016\/j.bpa.2018.06.002_bib53","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.2042-7158.1975.tb09516.x","article-title":"The effect of \u03949-tetrahydrocannabinol, cannabidiol and cannabinol on ether anaesthesia in mice","volume":"27","author":"Malor","year":"1975","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib54","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bjp.0704296","article-title":"Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat","volume":"134","author":"Smith","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2004.03.045","article-title":"Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats","author":"Mcqueen","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib57","doi-asserted-by":"crossref","first-page":"14136","DOI":"10.1073\/pnas.96.24.14136","article-title":"Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors","volume":"96","author":"J\u00e1rai","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpa.2018.06.002_bib58","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/BF01922330","article-title":"A\u00a0cannabinoid with cardiovascular activity but no overt behavioral effects","volume":"33","author":"Adams","year":"1977","journal-title":"Experientia"},{"key":"10.1016\/j.bpa.2018.06.002_bib59","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid- \u03b2 immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis","author":"Mo","year":"2017","journal-title":"Ann Clin Translat Neurol"},{"key":"10.1016\/j.bpa.2018.06.002_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimer\u2019s Dement Translat Res Clin Interv"},{"key":"10.1016\/j.bpa.2018.06.002_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bpa.2018.06.002_bib62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0140-6736(97)12331-5","article-title":"Calcium","volume":"352","author":"Bushinsky","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2018.06.002_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's disease: from pathogenesis to pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpa.2018.06.002_bib64","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1523\/JNEUROSCI.1788-16.2017","article-title":"Prying into the prion hypothesis for Parkinson's disease","volume":"37","author":"Brundin","year":"2017","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpa.2018.06.002_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib66","article-title":"Indications and usage gocovriTM is indicated for the treatment of dyskinesia in patients with Parkinson \u2019 s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications","year":"1968","journal-title":"Dosing Inf Initial Daily Dosage G"},{"key":"10.1016\/j.bpa.2018.06.002_bib67","first-page":"1","article-title":"Author Correction to: pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease","volume":"5102","author":"Elmer","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bpa.2018.06.002_bib68","first-page":"941","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study) a randomized clinical trial","volume":"5102","author":"Pahwa","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bpa.2018.06.002_bib69","first-page":"904","article-title":"Parkinson \u2019 s disease and anaesthesia","volume":"89","author":"Complete","year":"2002","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.bpa.2018.06.002_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00000542-200401000-00022","article-title":"Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy","volume":"100","author":"Snijdelaar","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bpa.2018.06.002_bib71","first-page":"e35900","article-title":"Effect of preoperative oral amantadine on acute and chronic postoperative pain after mandibular fracture surgery","volume":"6","author":"Yazdani","year":"2016","journal-title":"Anesthesiol Pain Med"},{"key":"10.1016\/j.bpa.2018.06.002_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.egja.2012.09.001","article-title":"Effect of preoperative oral amantadine on intraoperative anesthetic and analgesic requirements in female patients during abdominoplasty","volume":"29","author":"Abdelmawgoud","year":"2013","journal-title":"Egypt J Anaesth"},{"key":"10.1016\/j.bpa.2018.06.002_bib73","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bpa.2018.06.002_bib74","first-page":"368","article-title":"Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson's disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.bpa.2018.06.002_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","volume":"6","author":"Zhang","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bpa.2018.06.002_bib76","series-title":"NuplazidTM [package insert]","first-page":"1","year":"2016"},{"key":"10.1016\/j.bpa.2018.06.002_bib77","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bpa.2018.06.002_bib78","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/14737175.2016.1158102","article-title":"The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease","volume":"16","author":"Hermanowicz","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.bpa.2018.06.002_bib79","series-title":"Fda, Cder. XADAGO (safinamide) tablets, for oral use","year":"2017"},{"key":"10.1016\/j.bpa.2018.06.002_bib80","first-page":"668","article-title":"Parkinson's disease and its management: Part 3: nondopaminergic and Nonpharmacological treatment options","volume":"40","author":"DeMaagd","year":"2015","journal-title":"P\u00a0T"},{"key":"10.1016\/j.bpa.2018.06.002_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.251","article-title":"Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease","volume":"4","author":"Loprete","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bpa.2018.06.002_bib82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of safinamide","volume":"56","author":"M\u00fcller","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpa.2018.06.002_bib83","first-page":"622","article-title":"Xadago (safinamide): a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson's disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.bpa.2018.06.002_bib84","first-page":"165","article-title":"Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson's disease fluctuating patients: post hoc analyses of studies 016 and settle","volume":"6","author":"Cattaneo","year":"2016","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.bpa.2018.06.002_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Best Practice &amp; Research Clinical Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689618300491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521689618300491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:36:58Z","timestamp":1776397018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521689618300491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521689618300491"],"URL":"https:\/\/doi.org\/10.1016\/j.bpa.2018.06.002","relation":{},"ISSN":["1753-3740"],"issn-type":[{"value":"1753-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative implications of common and newer psychotropic medications used in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Anaesthesiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpa.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}